Data Set Name: alldata.sas7bdat

Num	Variable	Type	Len	Label
1	SUBJECT_ID	Char	9	Subject ID
2	REDCAP_REPEAT_INSTANCE	Num	8	Repeat Instance
3	REDCAP_REPEAT_INSTRUMENT	Char	500	Repeat Instrument
4	RAND_TRT	Num	8	
5	IE_VERSION	Char	500	IE form version
6	IE_IOK	Num	8	Did the patient meet all inclusion criteria? Age _18 years Currently hospitalized or in an emergency department with anticipated hospitalization. Symptoms of acute respiratory infection, defined as one or more of the following: cough fever (> 37.5° C / 9
7	IE_IOK_V2	Num	8	Did the patient meet all inclusion criteria?Age _18 yearsCurrently hospitalized or in an emergency department with anticipated hospitalization.Symptoms of acute respiratory infection, defined as one or more of the following: coughfever (> 37.5° C / 99.5° F
8	IE_ARISYMPTOMS___COU	Num	8	Which symptoms of acute respiratory infection does the patient present? (choice=Cough)
9	IE_ARISYMPTOMS___FEV	Num	8	Which symptoms of acute respiratory infection does the patient present? (choice=Fever (> 37.5° C / 99.5° F))
10	IE_ARISYMPTOMS___SOB	Num	8	Which symptoms of acute respiratory infection does the patient present? (choice=Shortness of breath)
11	IE_ARISYMPTOMS___ST	Num	8	Which symptoms of acute respiratory infection does the patient present? (choice=Sore throat)
12	IE_LABSTATUS	Num	8	Specify the laboratory confirmation status:
13	IE_EPRIS	Num	8	Prisoner
14	IE_EPREG	Num	8	Pregnant
15	IE_EBREAST	Num	8	Breast feeding
16	IE_EARI	Num	8	Symptoms of acute respiratory infection for >10 days before randomization
17	IE_ELATE	Num	8	More than 48 hours from hospitalization
18	IE_ESEIZURE	Num	8	Seizure disorder
19	IE_EPORPHYRIA	Num	8	Porphyria cutanea tarda
20	IE_ELONGQT	Num	8	Diagnosis of Long QT syndrome
21	IE_EQTC500	Num	8	QTc >500 ms on electrocardiogram within 72 hours prior to randomization
22	IE_EALLERGY	Num	8	Known allergy to hydroxychloroquine, chloroquine, or amodiaquine
23	IE_ECONTRA	Num	8	Receipt in the 12 hours prior to randomization, or planned administration during the 5-day study period, of a contraindicated medication that treating clinicians feel cannot be substituted (any of the following): Amiodarone Cimetidine Dofetilide Phenobarb
24	IE_ECHLOR	Num	8	Receipt of >1 dose of hydroxychloroquine or chloroquine in the 10 days prior to randomization
25	IE_ENPO	Num	8	Inability to receive enteral medications
26	IE_ENOCONTACT	Num	8	Refusal or Iinability to be contacted on Day 15 for clinical outcome assessment if discharged prior to Day 15
27	IE_PREVENROLL	Num	8	Previous enrollment in this trial

Num	Variable	Type	Len	Label
28	IE_EQUIPOISE	Num	8	The treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient
29	IE_NENE	Num	8	Not excluded but not enrolled
30	IE_NENESPEC	Char	5000	Please explain why the patient was not enrolled:
31	IE_ELIGIBLE	Num	8	Patient is eligible (1=yes, 0=no)
32	IE_APPROVED	Num	8	Did the treating clinicians provide permission to approach patient/LAR for informed consent discussion
33	IE_ENROLLED	Num	8	Was the patient enrolled?
34	IE_NOTENROLLEDREAS	Num	8	Reason not enrolled?
35	IE_NOTENROLLEDREAS_OTHER	Char	5000	If Other please describe:
36	CONS_CERTIFY	Num	8	Before randomization, the enrolling investigator must certify that that all of the following are true: Patient met all inclusion criteria Patient met no exclusion criteria Study Informed Consent Document/Form (ICD/ICF) were explained and reviewed with the
37	RAND_DT	Num	8	Randomization day
38	RAND_TM	Num	8	Randomization time
39	BL_AGE	Num	8	Age (patient must be at least 18 years of age)
40	BL_SEX	Num	8	Sex
41	BL_ETHNIC	Num	8	Ethnicity
42	BL_RACE___1	Num	8	Race (Check all that apply) (choice=Black or African American)
43	BL_RACE___OTHCAT	Num	8	Race (Check all that apply) (choice=American Indian or Alaska Native/Asian/Native Hawaiian or Other Pacific Islander)
44	BL_RACE___5	Num	8	Race (Check all that apply) (choice=White or Caucasian)
45	BL_RACE___6	Num	8	Race (Check all that apply) (choice=Other)
46	BL_HEIGHT	Num	8	Height (cm)
47	BL_WEIGHT	Num	8	Weight (kg)
48	BL_SYMPTOMDT	Num	8	Day of symptom onset
49	BL_HOSPADMDT	Num	8	Day of presentation to the study hospital
50	BL_HOSPADMTM	Num	8	Time of presentation to the study hospital
51	BL_PREHOSP	Num	8	Source of presentation to study hospital (select one)
52	BL_RANDLOC	Num	8	Location at randomization
53	BL_EKGQTC	Num	8	What was the QTc on the EKG prior to randomization? (ms)
54	BL_EKGDT	Num	8	What was the day of the EKG prior to randomization?
55	BL_EKGTM	Num	8	What was the time of the EKG prior to randomization?
56	CHARL_LEUK	Num	8	Leukemia (AML, CML, ALL, multiple myeloma)
57	CHARL_LYMPH	Num	8	Malignant lymphoma
58	CHARL_HEMIPLEGIA	Num	8	Hemiplegia
59	CHARL_CEREBVASC	Num	8	Cerebrovascular disease
60	CHARL_MYOINFARC	Num	8	A prior myocardial infarction
61	CHARL_CONGHEART	Num	8	Congestive heart failure
62	CHARL_PERIVASC	Num	8	Peripheral vascular disease

Num	Variable	Type	Len	Label
63	CHARL_DEMENTIA	Num	8	Dementia
64	CHARL_COPD	Num	8	COPD
65	CHARL_ASTHMA	Num	8	Asthma
66	CHART_OXYGEN	Num	8	Chronic receipt of supplemental oxygen prior to current illness Supplemental oxygen is defined as oxygen administered by nasal cannula, face mask, high-flow nasal cannula, non-invasive ventilation, or invasive ventilation. Positive airway pressure (CPAP o
67	CHARL_CONTIS	Num	8	Connective tissue disease
68	CHARL_ULCER	Num	8	Peptic ulcer disease
69	CHARL_HYPERTENSION	Num	8	History of hypertension
70	CHARL_CAD	Num	8	Coronary artery disease
71	CHARL_FATAL	Num	8	Rapidly fatal disease
72	CHARL_TUMOR	Num	8	Solid tumor
73	CHARL_LIVER	Num	8	Liver disease
74	CHARL_DIABETES	Num	8	Diabetes mellitus (DM)
75	CHARL_KIDNEY	Num	8	Moderate to severe kidney disease
76	CHARL_SMOKING	Num	8	Cigarette or tobacco smoking
77	CHARL_VAPING	Num	8	Vaping
78	RXHX_CORTICO	Num	8	Does the patient take corticosteroids as a home medication?
79	RXHX_ACE	Num	8	Does the patient take ACE inhibitors as a home medication?
80	RXHX_ARB	Num	8	Does the patient take angiotensin receptor blockers as a home medication?
81	RXHX_NSAIDS	Num	8	Does the patient regularly take non-steroidal anti-inflammatory drugs as a home medication?
82	VIT_HRH_1	Num	8	Highest heart rate, bpm
83	VIT_SPBL_1	Num	8	Lowest systolic blood pressure, mm Hg
84	VIT_VASOP_1	Num	8	Receipt of vasopressors
85	VIT_RRH_1	Num	8	Highest respiratory rate, breaths per minute
86	VIT_SPO2L_1	Num	8	Lowest SpO2
87	VIT_FIO2H_1	Num	8	Highest FiO2For patients on nasal cannula, use estimation that FIO2 = 0.21 + 0.03*(LPM of NC O2)
88	VIT_RESPSUP_1	Num	8	Respiratory support at enrollment (select one)
89	SOFA_PAO2L_1	Num	8	Lowest PaO2
90	SOFA_PAO2LFIO2_1	Num	8	Value for FiO2 at the time of lowest PaO2For patients on nasal cannula, use estimation that FIO2 = 0.21 + 0.03*(LPM of NC O2)
91	SOFA_SPO2L_1	Num	8	Lowest SpO2
92	SOFA_SPO2LFIO2_1	Num	8	Value for FiO2 at the time of lowest SpO2For patients on nasal cannula, use estimation that FIO2 = 0.21 + 0.03*(LPM of NC O2)
93	SOFA_PLATL_1	Num	8	Lowest platelet count, per mm3 (in thousands)
94	SOFA_BILIH_1	Num	8	Highest bilirubin, mg/dL
95	SOFA_GCS_1	Num	8	Lowest Glasgow Coma Scale score
96	SOFA_MAPL_1	Num	8	Lowest mean arterial pressure, mmHg

Num	Variable	Type	Len	Label
97	SOFA_VASOYN_1	Num	8	Receipt of vasopressors
98	SOFA_VASO_1___DOBUT	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Dobutamine)
99	SOFA_VASO_1___DOPA	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Dopamine)
100	SOFA_VASO_1___EPI	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Epinephrine)
101	SOFA_VASO_1___NEOSYN	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Neosynephrine)
102	SOFA_VASO_1___NOREPI	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Norepinephrine)
103	SOFA_VASO_1___VASOP	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Vasopressin)
104	SOFA_DOBUT_1	Num	8	Dobutamine dose: (mcg/kg/min)
105	SOFA_DOPA_1	Num	8	Dopamine dose: (mcg/kg/min)
106	SOFA_EPI_1	Num	8	Epinephrine dose: (mcg/kg/min)
107	SOFA_NOREPI_1	Num	8	Norepinephrine dose: (mcg/kg/min)
108	SOFA_NEOSYN_1	Num	8	Neosynephrine dose: (mcg/kg/min)
109	SOFA_VASOP_1	Num	8	Vasopressin dose: (mcg/kg/min)
110	SOFA_CREATH_1	Num	8	Highest creatinine, mg/dL
111	SOFA_UOUT_1	Num	8	Urine output (estimated)
112	SOFA_INRH_1	Num	8	Highest international normalized ratio (INR)
113	LABS_YN_1	Num	8	Were the daily labs available for this study day? (Day 1)
114	LABS_NOREAS_1	Char	5000	If no, why not? (Day 1)
115	LABS_WBCH_1	Num	8	Highest white blood cell count (/mm3) (Day 1)
116	LABS_WBCL_1	Num	8	Lowest white blood cell count (/mm3) (Day 1)
117	LABS_HEMOL_1	Num	8	Lowest hemoglobin (g/dl) (Day 1)
118	LABS_SODIUMH_1	Num	8	Highest sodium (mEq/L) (Day 1)
119	LABS_SODIUML_1	Num	8	Lowest sodium (mEq/L) (Day 1)
120	LABS_POTASSIUMH_1	Num	8	Highest potassium (mEq/L) (Day 1)
121	LABS_POTASSIUML_1	Num	8	Lowest potassium (mEq/L) (Day 1)
122	LABS_CHLORIDEH_1	Num	8	Highest chloride (mEq/L) (Day 1)
123	LABS_BICARBONATEH_1	Num	8	Highest bicarbonate (mEq/L) (Day 1)
124	LABS_BICARBONATEL_1	Num	8	Lowest bicarbonate (mEq/L) (Day 1)
125	LABS_BUNH_1	Num	8	Highest BUN - Blood Urea Nitrogen (mg/dL) (Day 1)
126	LABS_TROPH_1	Num	8	Highest troponin (mg/dL) (Day 1)
127	LABS_ASTH_1	Num	8	Highest AST - Aspartate aminotransferase (units per liter) (Day 1)
128	LABS_ALTH_1	Num	8	Highest ALT - Alanine aminotransferase (units per liter) (Day 1)
129	LABS_ALPH_1	Num	8	Highest ALP - Alkaline Phosphatase (IU/L) (Day 1)
130	LABS_ALBUMINL_1	Num	8	Lowest albumin (g/dL) (Day 1)
131	LABS_PTTH_1	Num	8	Highest PTT - Partial Thromboplastin Time (seconds) (Day 1)

Num	Variable	Type	Len	Label
132	PRMED_CHLOR	Num	8	Chloroquine (up to randomization)
133	PRMED_HYDROXYCHLOR	Num	8	Hydroxychloroquine (up to randomization)
134	PRMED_REMDESIVIR	Num	8	Remdesivir (up to randomization)
135	PRMED_LOPINAVIR	Num	8	Lopinavir/ritonavir (up to randomization)
136	PRMED_CORTICOSTER	Num	8	Corticosteroids (up to randomization)
137	PRMED_TOCILIZUMAB	Num	8	Tocilizumab (up to randomization)
138	PRMED_SARILUMAB	Num	8	Sarilumab (up to randomization)
139	PRMED_INTERFERON	Num	8	Interferon _ (up to randomization)
140	PRMED_AZITHRO	Num	8	Azithromycin (up to randomization)
141	PRMED_OTHER	Num	8	Other medication(s) between hospital admission and randomization felt to be relevant to trial?
142	PRMED_OTHERSPEC	Char	5000	If other medication(s), which medication(s)?
143	PRTRT_CONPLAS	Num	8	Convalescent plasma (up to randomization)?
144	PRTRT_IMMGLOB	Num	8	SARS-CoV-2 hyperimmune globulin (up to randomization)?
145	PRTRT_MONOCANTI	Num	8	Monoclonal antibodies (up to randomization)?
146	COVID_OOSCALE_1	Num	8	COVID Ordinal Outcomes Scale at randomization
147	DOSE_YN_1	Num	8	Was dose 1 of study medication given?Dose 1 is scheduled to be given 4 hours after randomization
148	DOSE_DT_1	Num	8	Day dose 1 administered
149	DOSE_TM_1	Num	8	Time dose 1 administered
150	DOSE_INT_1	Num	8	Hours since randomization
151	DOSE_NOTADM_1	Num	8	Reason study drug dose 1 not administered
152	DOSE_NOTADMOTH_1	Char	5000	Other reason study drug dose 1 not administered
153	DOSE_NOTADMSPEC_1	Char	5000	Please give detailed description of why study drug dose 1 was not administered
154	DOSE_YN_2	Num	8	Was dose 2 of study medication given?Dose 2 is scheduled to be given between 8 and 16 hours after prior scheduled dose
155	DOSE_DT_2	Num	8	Day dose 2 administered
156	DOSE_TM_2	Num	8	Time dose 2 administered
157	DOSE_INT_2	Num	8	Hours since last dose:
158	DOSE_NOTADM_2	Num	8	Reason study drug dose 2 not administered
159	DOSE_NOTADMOTH_2	Char	5000	Other reason study drug dose 2 not administered
160	DOSE_NOTADMSPEC_2	Char	5000	Please give detailed description of why study drug dose 2 was not administered
161	DOSE_YN_3	Num	8	Was dose 3 of study medication given?Dose 3 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
162	DOSE_DT_3	Num	8	Day dose 3 administered
163	DOSE_TM_3	Num	8	Time dose 3 administered
164	DOSE_INT_3	Num	8	Hours since last dose:
165	DOSE_NOTADM_3	Num	8	Reason study drug dose 3 not administered
166	DOSE_NOTADMOTH_3	Char	5000	Other reason study drug dose 3 not administered
167	DOSE_NOTADMSPEC_3	Char	5000	Please give detailed description of why study drug dose 3 was not administered

Num	Variable	Type	Len	Label
168	DOSE_YN_4	Num	8	Was dose 4 of study medication given?Dose 4 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
169	DOSE_DT_4	Num	8	Day dose 4 administered
170	DOSE_TM_4	Num	8	Time dose 4 administered
171	DOSE_INT_4	Num	8	Hours since last dose:
172	DOSE_NOTADM_4	Num	8	Reason study drug dose 4 not administered
173	DOSE_NOTADMOTH_4	Char	5000	Other reason study drug dose 4 not administered
174	DOSE_NOTADMSPEC_4	Char	5000	Please give detailed description of why study drug dose 4 was not administered
175	DOSE_YN_5	Num	8	Was dose 5 of study medication given?Dose 5 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
176	DOSE_DT_5	Num	8	Day dose 5 administered
177	DOSE_TM_5	Num	8	Time dose 5 administered
178	DOSE_INT_5	Num	8	Hours since last dose:
179	DOSE_NOTADM_5	Num	8	Reason study drug dose 5 not administered
180	DOSE_NOTADMOTH_5	Char	5000	Other reason study drug dose 5 not administered
181	DOSE_NOTADMSPEC_5	Char	5000	Please give detailed description of why study drug dose 5 was not administered
182	DOSE_YN_6	Num	8	Was dose 6 of study medication given?Dose 6 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
183	DOSE_DT_6	Num	8	Day dose 6 administered
184	DOSE_TM_6	Num	8	Time dose 6 administered
185	DOSE_INT_6	Num	8	Hours since last dose:
186	DOSE_NOTADM_6	Num	8	Reason study drug dose 6 not administered
187	DOSE_NOTADMOTH_6	Char	5000	Other reason study drug dose 6 not administered
188	DOSE_NOTADMSPEC_6	Char	5000	Please give detailed description of why study drug dose 6 was not administered
189	DOSE_YN_7	Num	8	Was dose 7 of study medication given?Dose 7 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
190	DOSE_DT_7	Num	8	Day dose 7 administered
191	DOSE_TM_7	Num	8	Time dose 7 administered
192	DOSE_INT_7	Num	8	Hours since last dose:
193	DOSE_NOTADM_7	Num	8	Reason study drug dose 7 not administered
194	DOSE_NOTADMOTH_7	Char	5000	Other reason study drug dose 7 not administered
195	DOSE_NOTADMSPEC_7	Char	5000	Please give detailed description of why study drug dose 7 was not administered
196	DOSE_YN_8	Num	8	Was dose 8 of study medication given?Dose 8 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
197	DOSE_DT_8	Num	8	Day dose 8 administered
198	DOSE_TM_8	Num	8	Time dose 8 administered
199	DOSE_INT_8	Num	8	Hours since last dose:
200	DOSE_NOTADM_8	Num	8	Reason study drug dose 8 not administered
201	DOSE_NOTADMOTH_8	Char	5000	Other reason study drug dose 8 not administered
202	DOSE_NOTADMSPEC_8	Char	5000	Please give detailed description of why study drug dose 8 was not administered

Num	Variable	Type	Len	Label
203	DOSE_YN_9	Num	8	Was dose 9 of study medication given?Dose 9 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
204	DOSE_DT_9	Num	8	Day dose 9 administered
205	DOSE_TM_9	Num	8	Time dose 9 administered
206	DOSE_INT_9	Num	8	Hours since last dose:
207	DOSE_NOTADM_9	Num	8	Reason study drug dose 9 not administered
208	DOSE_NOTADMOTH_9	Char	5000	Other reason study drug dose 9 not administered
209	DOSE_NOTADMSPEC_9	Char	5000	Please give detailed description of why study drug dose 9 was not administered
210	DOSE_YN_10	Num	8	Was dose 10 of study medication given?Dose 10 is scheduled to be given between 8 and 16 hours after prior scheduled dose.
211	DOSE_DT_10	Num	8	Day dose 10 administered
212	DOSE_TM_10	Num	8	Time dose 10 administered
213	DOSE_INT_10	Num	8	Hours since last dose:
214	DOSE_NOTADM_10	Num	8	Reason study drug dose 10 not administered
215	DOSE_NOTADMOTH_10	Char	5000	Other reason study drug dose 10 not administered
216	DOSE_NOTADMSPEC_10	Char	5000	Please give detailed description of why study drug dose 10 was not administered
217	EKG_STUDYYN_3	Num	8	Was an assessment of QTc with EKG or rhythm strip performed 24-48 hours after first administration of study drug?
218	EKG_STUDYDT_3	Num	8	Day of EKG or rhythm strip from which QTc was assessed
219	EKG_STUDYTM_3	Num	8	Time of EKG or rhythm strip from which QTc was assessed
220	EKG_STUDYQTC_3	Num	8	Value for QTc, ms
221	EKG_STUDYNO_3	Num	8	Why was an assessment of QTc not performed 24-48 hours after first administration of study drug?
222	EKG_STUDYNOREAS_3	Char	5000	Describe why assessment of QTc was not performed at 24-48 hours after first dose of study drug
223	IH_YN_2	Num	8	Was the patient located in the study hospital at any time on study day 2 (i.e., admitted, inpatient)?
224	COVID_OOSCALE_2	Num	8	COVID Ordinal Outcomes Scale on Day 2Select the lowest value that occurred on this study day
225	IH_CONTRA_2	Num	8	Contraindicated Medications Day 2Review the electronic health record for orders or administration of the following medications that are considered CONTRAINDICATED:amiodaronechloroquinecimetidinedofetilidephenobarbitalphenytoinsotalol
226	IH_CONTRAOCCUR_2	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a CONTRAINDICATED medication
227	IH_INTERACT_2	Num	8	Medication Interaction Day 2On this study day, review the electronic health record for orders or administration of the following medications that are considered to have a potential interaction with study drug:ampicillinantacidscyclosporinedigoxinflecainide
228	IH_INTERACTOCCUR_2	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a medication with a potential interaction
229	IH_AEASSESS_2	Num	8	Adverse Event Assessment Study Day 2On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
230	IH_AEASSESSREAS_2	Char	5000	Why were AEs not assessed?

Num	Variable	Type	Len	Label
231	IH_SAFEASSESS_2	Num	8	Safety Outcome Assessment Study Day 2On this study day, study personnel assessed for the occurrence of safety outcomes that might prompt discontinuation of the study drug (and if found recorded in Safety Outcomes CRF).
232	IH_SAFEASSESSREAS_2	Char	5000	Why were safety outcomes not assessed?
233	LABS_YN_2	Num	8	Were the daily labs available for this study day? (Day 2)
234	LABS_NOREAS_2	Char	5000	If no, why? (Day 2)
235	LABS_WBCH_2	Num	8	Highest white blood cell count (/mm3) (Day 2)
236	LABS_WBCL_2	Num	8	Lowest white blood cell count (/mm3) (Day 2)
237	LABS_HEMOL_2	Num	8	Lowest hemoglobin (g/dl) (Day 2)
238	LABS_PLATELETL_2	Num	8	Lowest platelet count (/mm3; in thousands) (Day 2)
239	LABS_SODIUMH_2	Num	8	Highest sodium (mEq/L) (Day 2)
240	LABS_SODIUML_2	Num	8	Lowest sodium (mEq/L) (Day 2)
241	LABS_POTASSIUMH_2	Num	8	Highest potassium (mEq/L) (Day 2)
242	LABS_POTASSIUML_2	Num	8	Lowest potassium (mEq/L) (Day 2)
243	LABS_CHLORIDEH_2	Num	8	Highest chloride (mEq/L) (Day 2)
244	LABS_BICARBONATEH_2	Num	8	Highest bicarbonate (mEq/L) (Day 2)
245	LABS_BICARBONATEL_2	Num	8	Lowest bicarbonate (mEq/L) (Day 2)
246	LABS_BUNH_2	Num	8	Highest BUN - Blood Urea Nitrogen (mg/dL) (Day 2)
247	LABS_CREATH_2	Num	8	Highest creatinine (mg/dL) (Day 2)
248	LABS_TROPH_2	Num	8	Highest troponin (mg/dL) (Day 2)
249	LABS_ASTH_2	Num	8	Highest AST - Aspartate aminotransferase (units per liter) (Day 2)
250	LABS_ALTH_2	Num	8	Highest ALT - Alanine aminotransferase (units per liter) (Day 2)
251	LABS_ALPH_2	Num	8	Highest ALP - Alkaline Phosphatase (IU/L) (Day 2)
252	LABS_TOTBILIH_2	Num	8	Highest total bilirubin (mg/dL) (Day 2)
253	LABS_ALBUMINL_2	Num	8	Lowest albumin (g/dL) (Day 2)
254	LABS_PTTH_2	Num	8	Highest PTT - Partial Thromboplastin Time (seconds) (Day 2)
255	LABS_INRH_2	Num	8	Highest INR - International Normalized Ratio (Day 2)
256	EKG_CLINYN_2	Num	8	Was a clinical EKG performed on this study day?
257	EKG_CLINDT_2	Num	8	Day of EKG or rhythm strip from which QTc was assessed
258	EKG_CLINTM_2	Num	8	Time of EKG or rhythm strip from which QTc was assessed
259	EKG_CLINQTC_2	Num	8	Value for QTc, ms
260	IH_YN_3	Num	8	Was the patient located in the study hospital at any time on study day 3 (i.e., admitted, inpatient)?
261	COVID_OOSCALE_3	Num	8	COVID Ordinal Outcomes Scale on Day 3Select the lowest value that occurred on this study day
262	IH_CONTRA_3	Num	8	Contraindicated Medications Day 3Review the electronic health record for orders or administration of the following medications that are considered CONTRAINDICATED:amiodaronechloroquinecimetidinedofetilidephenobarbitalphenytoinsotalol
263	IH_CONTRAOCCUR_3	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a CONTRAINDICATED medication

Num	Variable	Type	Len	Label
264	IH_INTERACT_3	Num	8	Medication Interaction Day 2On this study day, review the electronic health record for orders or administration of the following medications that are considered to have a potential interaction with study drug:ampicillinantacidscyclosporinedigoxinflecainide
265	IH_INTERACTOCCUR_3	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a medication with a potential interaction
266	IH_AEASSESS_3	Num	8	Adverse Event Assessment Study Day 3On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
267	IH_AEASSESSREAS_3	Char	5000	Why were AEs not assessed?
268	IH_SAFEASSESS_3	Num	8	Safety Outcome Assessment Study Day 3On this study day, study personnel assessed for the occurrence of safety outcomes that might prompt discontinuation of the study drug (and if found recorded in Safety Outcomes CRF).
269	IH_SAFEASSESSREAS_3	Char	5000	Why were safety outcomes not assessed?
270	SOFA_PAO2L_3	Num	8	Lowest PaO2
271	SOFA_PAO2LFIO2_3	Num	8	Value for FiO2 at the time of lowest PaO2For patients on nasal cannula, use estimation that FIO2 = 0.21 + 0.03*(LPM of NC O2)
272	SOFA_SPO2L_3	Num	8	Lowest SpO2
273	SOFA_SPO2LFIO2_3	Num	8	Value for FiO2 at the time of lowest SpO2For patients on nasal cannula, use estimation that FIO2 = 0.21 + 0.03*(LPM of NC O2)
274	SOFA_PLATL_3	Num	8	Lowest platelet count, per mm3 (in thousands)
275	SOFA_BILIH_3	Num	8	Highest bilirubin, mg/dL
276	SOFA_GCS_3	Num	8	Lowest Glasgow Coma Scale score
277	SOFA_MAPL_3	Num	8	Lowest mean arterial pressure, mmHg
278	SOFA_VASOYN_3	Num	8	Receipt of vasopressors
279	SOFA_VASO_3___DOBUT	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Dobutamine)
280	SOFA_VASO_3___DOPA	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Dopamine)
281	SOFA_VASO_3___EPI	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Epinephrine)
282	SOFA_VASO_3___NEOSYN	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Neosynephrine)
283	SOFA_VASO_3___NOREPI	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Norepinephrine)
284	SOFA_VASO_3___VASOP	Num	8	Which vasopressors did the patient receive in the last 24 hours? (choice=Vasopressin)
285	SOFA_DOBUT_3	Num	8	Dobutamine dose: (mcg/kg/min)
286	SOFA_DOPA_3	Num	8	Dopamine dose: (mcg/kg/min)
287	SOFA_EPI_3	Num	8	Epinephrine dose: (mcg/kg/min)
288	SOFA_NOREPI_3	Num	8	Norepinephrine dose: (mcg/kg/min)
289	SOFA_NEOSYN_3	Num	8	Neosynephrine dose: (mcg/kg/min)
290	SOFA_VASOP_3	Num	8	Vasopressin dose: (mcg/kg/min)
291	SOFA_CREATH_3	Num	8	Highest creatinine, mg/dL

Num	Variable	Type	Len	Label
292	SOFA_UOUT_3	Num	8	Urine output (estimated)
293	SOFA_INRH_3	Num	8	Highest international normalized ratio (INR)
294	LABS_YN_3	Num	8	Were the daily labs available for this study day? (Day 3)
295	LABS_NOREAS_3	Char	5000	If no, why? (Day 3)
296	LABS_WBCH_3	Num	8	Highest white blood cell count (/mm3) (Day 3)
297	LABS_WBCL_3	Num	8	Lowest white blood cell count (/mm3) (Day 3)
298	LABS_HEMOL_3	Num	8	Lowest hemoglobin (g/dl) (Day 3)
299	LABS_SODIUMH_3	Num	8	Highest sodium (mEq/L) (Day 3)
300	LABS_SODIUML_3	Num	8	Lowest sodium (mEq/L) (Day 3)
301	LABS_POTASSIUMH_3	Num	8	Highest potassium (mEq/L) (Day 3)
302	LABS_POTASSIUML_3	Num	8	Lowest potassium (mEq/L) (Day 3)
303	LABS_CHLORIDEH_3	Num	8	Highest chloride (mEq/L) (Day 3)
304	LABS_BICARBONATEH_3	Num	8	Highest bicarbonate (mEq/L) (Day 3)
305	LABS_BICARBONATEL_3	Num	8	Lowest bicarbonate (mEq/L) (Day 3)
306	LABS_BUNH_3	Num	8	Highest BUN - Blood Urea Nitrogen (mg/dL) (Day 3)
307	LABS_TROPH_3	Num	8	Highest troponin (mg/dL) (Day 3)
308	LABS_ASTH_3	Num	8	Highest AST - Aspartate aminotransferase (units per liter) (Day 3)
309	LABS_ALTH_3	Num	8	Highest ALT - Alanine aminotransferase (units per liter) (Day 3)
310	LABS_ALPH_3	Num	8	Highest ALP - Alkaline Phosphatase (IU/L) (Day 3)
311	LABS_ALBUMINL_3	Num	8	Lowest albumin (g/dL) (Day 3)
312	LABS_PTTH_3	Num	8	Highest PTT - Partial Thromboplastin Time (seconds) (Day 3)
313	EKG_CLINYN_3	Num	8	Was a clinical EKG performed on this study day?
314	EKG_CLINOBT_3	Num	8	Were any of the clinically obtained EKGs obtained between 24 and 48 hours after the first administration of the study drug?
315	EKG_CLINDT_3	Num	8	Day of EKG or rhythm strip from which QTc was assessed
316	EKG_CLINTM_3	Num	8	Time of EKG or rhythm strip from which QTc was assessed
317	EKG_CLINQTC_3	Num	8	Value for QTc, ms
318	IH_YN_4	Num	8	Was the patient located in the study hospital at any time on study day 4 (i.e., admitted, inpatient)?
319	COVID_OOSCALE_4	Num	8	COVID Ordinal Outcomes Scale on Day 4Select the lowest value that occurred on this study day
320	IH_CONTRA_4	Num	8	Contraindicated Medications Day 4Review the electronic health record for orders or administration of the following medications that are considered CONTRAINDICATED:amiodaronechloroquinecimetidinedofetilidephenobarbitalphenytoinsotalol
321	IH_CONTRAOCCUR_4	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a CONTRAINDICATED medication
322	IH_INTERACT_4	Num	8	Medication Interaction Day 4On this study day, review the electronic health record for orders or administration of the following medications that are considered to have a potential interaction with study drug:ampicillinantacidscyclosporinedigoxinflecainide
323	IH_INTERACTOCCUR_4	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a medication with a potential interaction

Num	Variable	Type	Len	Label
324	IH_AEASSESS_4	Num	8	Adverse Event Assessment Study Day 4On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
325	IH_AEASSESSREAS_4	Char	5000	Why were AEs not assessed?
326	IH_SAFEASSESS_4	Num	8	Safety Outcome Assessment Study Day 4On this study day, study personnel assessed for the occurrence of safety outcomes that might prompt discontinuation of the study drug (and if found recorded in Safety Outcomes CRF).
327	IH_SAFEASSESSREAS_4	Char	5000	Why were safety outcomes not assessed?
328	LABS_YN_4	Num	8	Were the daily labs available for this study day? (Day 4)
329	LABS_NOREAS_4	Char	5000	If no, why? (Day 4)
330	LABS_WBCH_4	Num	8	Highest white blood cell count (/mm3) (Day 4)
331	LABS_WBCL_4	Num	8	Lowest white blood cell count (/mm3) (Day 4)
332	LABS_HEMOL_4	Num	8	Lowest hemoglobin (g/dl) (Day 4)
333	LABS_PLATELETL_4	Num	8	Lowest platelet count (/mm3; in thousands) (Day 4)
334	LABS_SODIUMH_4	Num	8	Highest sodium (mEq/L) (Day 4)
335	LABS_SODIUML_4	Num	8	Lowest sodium (mEq/L) (Day 4)
336	LABS_POTASSIUMH_4	Num	8	Highest potassium (mEq/L) (Day 4)
337	LABS_POTASSIUML_4	Num	8	Lowest potassium (mEq/L) (Day 4)
338	LABS_CHLORIDEH_4	Num	8	Highest chloride (mEq/L) (Day 4)
339	LABS_BICARBONATEH_4	Num	8	Highest bicarbonate (mEq/L) (Day 4)
340	LABS_BICARBONATEL_4	Num	8	Lowest bicarbonate (mEq/L) (Day 4)
341	LABS_BUNH_4	Num	8	Highest BUN - Blood Urea Nitrogen (Day 4)
342	LABS_CREATH_4	Num	8	Highest creatinine (mg/dL) (Day 4)
343	LABS_TROPH_4	Num	8	Highest troponin (mg/dL) (Day 4)
344	LABS_ASTH_4	Num	8	Highest AST - Aspartate aminotransferase (units per liter) (Day 4)
345	LABS_ALTH_4	Num	8	Highest ALT - Alanine aminotransferase (units per liter) (Day 4)
346	LABS_ALPH_4	Num	8	Highest ALP - Alkaline Phosphatase (IU/L) (Day 4)
347	LABS_TOTBILIH_4	Num	8	Highest total bilirubin (mg/dL) (Day 4)
348	LABS_ALBUMINL_4	Num	8	Lowest albumin (g/dL) (Day 4)
349	LABS_PTTH_4	Num	8	Highest PTT - Partial Thromboplastin Time (seconds) (Day 4)
350	LABS_INRH_4	Num	8	Highest INR - International Normalized Ratio (Day 4)
351	EKG_CLINYN_4	Num	8	Was a clinical EKG performed on this study day?
352	EKG_CLINDT_4	Num	8	Day of EKG or rhythm strip from which QTc was assessed
353	EKG_CLINTM_4	Num	8	Time of EKG or rhythm strip from which QTc was assessed
354	EKG_CLINQTC_4	Num	8	Value for QTc, ms
355	IH_YN_5	Num	8	Was the patient located in the study hospital at any time on study day 5 (i.e., admitted, inpatient)?
356	COVID_OOSCALE_5	Num	8	COVID Ordinal Outcomes Scale on Day 5Select the lowest value that occurred on this study day

Num	Variable	Type	Len	Label
357	IH_CONTRA_5	Num	8	Contraindicated Medications Day 5Review the electronic health record for orders or administration of the following medications that are considered CONTRAINDICATED:amiodaronechloroquinecimetidinedofetilidephenobarbitalphenytoinsotalol
358	IH_CONTRAOCCUR_5	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a CONTRAINDICATED medication
359	IH_INTERACT_5	Num	8	Medication Interaction Day 5On this study day, review the electronic health record for orders or administration of the following medications that are considered to have a potential interaction with study drug:ampicillinantacidscyclosporinedigoxinflecainide
360	IH_INTERACTOCCUR_5	Char	5000	Describe what occurred when it was discovered that patient was receiving study drug and a medication with a potential interaction
361	IH_AEASSESS_5	Num	8	Adverse Event Assessment Study Day 5On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
362	IH_AEASSESSREAS_5	Char	5000	Why were AEs not assessed?
363	IH_SAFEASSESS_5	Num	8	Safety Outcome Assessment Study Day 5On this study day, study personnel assessed for the occurrence of safety outcomes that might prompt discontinuation of the study drug (and if found recorded in Safety Outcomes CRF).
364	IH_SAFEASSESSREAS_5	Char	5000	Why were safety outcomes not assessed?
365	LABS_YN_5	Num	8	Were the daily labs available for this study day? (Day 5)
366	LABS_NOREAS_5	Char	5000	If no, why? (Day 5)
367	LABS_WBCH_5	Num	8	Highest white blood cell count (/mm3) (Day 5)
368	LABS_WBCL_5	Num	8	Lowest white blood cell count (/mm3) (Day 5)
369	LABS_HEMOL_5	Num	8	Lowest hemoglobin (g/dl) (Day 5)
370	LABS_PLATELETL_5	Num	8	Lowest platelet count (Day 5)
371	LABS_SODIUMH_5	Num	8	Highest sodium (mEq/L) (Day 5)
372	LABS_SODIUML_5	Num	8	Lowest sodium (mEq/L) (Day 5)
373	LABS_POTASSIUMH_5	Num	8	Highest potassium (mEq/L) (Day 5)
374	LABS_POTASSIUML_5	Num	8	Lowest potassium (mEq/L) (Day 5)
375	LABS_CHLORIDEH_5	Num	8	Highest chloride (mEq/L) (Day 5)
376	LABS_BICARBONATEH_5	Num	8	Highest bicarbonate (mEq/L) (Day 5)
377	LABS_BICARBONATEL_5	Num	8	Lowest bicarbonate (mEq/L) (Day 5)
378	LABS_BUNH_5	Num	8	Highest BUN - Blood Urea Nitrogen (mg/dL) (Day 5)
379	LABS_CREATH_5	Num	8	Highest creatinine (mg/dL) (Day 5)
380	LABS_TROPH_5	Num	8	Highest troponin (mg/dL) (Day 5)
381	LABS_ASTH_5	Num	8	Highest AST - Aspartate aminotransferase (units per liter) (Day 5)
382	LABS_ALTH_5	Num	8	Highest ALT - Alanine aminotransferase (units per liter) (Day 5)
383	LABS_ALPH_5	Num	8	Highest ALP - Alkaline Phosphatase (IU/L) (Day 5)
384	LABS_TOTBILIH_5	Num	8	Highest total bilirubin (mg/dL) (Day 5)
385	LABS_ALBUMINL_5	Num	8	Lowest albumin (g/dL) (Day 5)
386	LABS_PTTH_5	Num	8	Highest PTT - Partial Thromboplastin Time (seconds) (Day 5)
387	LABS_INRH_5	Num	8	Highest INR - International Normalized Ratio (Day 5)

Num	Variable	Type	Len	Label
388	EKG_CLINYN_5	Num	8	Was a clinical EKG performed on this study day?
389	EKG_CLINDT_5	Num	8	Day of EKG or rhythm strip from which QTc was assessed
390	EKG_CLINDTM_5	Num	8	Time of EKG or rhythm strip from which QTc was assessed
391	EKG_CLINQTC_5	Num	8	Value for QTc, ms
392	OUT_OOSYN_8	Num	8	Was information on the COVID Ordinal Outcome Scale available at 8 days?
393	OUT_OOSNOSPEC_8	Char	5000	Please describe other reason why
394	OUT_SRC_8	Num	8	Primary source of of day 8 information
395	OUT_SRCSPEC_8	Char	5000	Other source of day 8 information
396	OUT_DT_8	Num	8	Day that 8 day assessment was performed
397	OUT_TM_8	Num	8	Time that 8 day assessment was performed
398	COVID_OOSCALE_8	Num	8	COVID Ordinal Outcomes Scale on Day 8Select the lowest value that occurred on this study day
399	OUT_SYMPYN_8	Num	8	Did the patient report any symptoms on day 8?
400	OUT_SYMP_8___COUGH	Num	8	Which symptoms did the patient report? (choice=Cough)
401	OUT_SYMP_8___CT	Num	8	Which symptoms did the patient report? (choice=Chest tightness)
402	OUT_SYMP_8___FEVER	Num	8	Which symptoms did the patient report? (choice=Fever (temperature > 99.5°F with a thermometer))
403	OUT_SYMP_8___FEVERISH	Num	8	Which symptoms did the patient report? (choice=Feeling feverish)
404	OUT_SYMP_8___OTH	Num	8	Which symptoms did the patient report? (choice=Other)
405	OUT_SYMP_8___SOB	Num	8	Which symptoms did the patient report? (choice=Shortness of breath)
406	OUT_SYMP_8___ST	Num	8	Which symptoms did the patient report? (choice=Sore throat)
407	OUT_SYMP_8___WEAK	Num	8	Which symptoms did the patient report? (choice=Weakness or fatigue)
408	OUT_SYMPOTH_8	Char	5000	Please specify:
409	OUT_AEASSESS_8	Num	8	Adverse Event Assessment Study Day 8On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
410	OUT_AEASSESSREAS_8	Char	5000	Why were AEs not assessed?
411	OUT_SAFEASSESS_8	Num	8	Safety Outcome Assessment Study Day 8On this study day, study personnel assessed for the occurrence of safety outcomes (and if found recorded in Safety Outcomes CRF).
412	OUT_SAFEASSESSREAS_8	Char	5000	Why were safety outcomes not assessed?
413	OUT_OOSYN_15	Num	8	Was information on the COVID Ordinal Outcome Scale available at 15 days?
414	OUT_OOSNOSPEC_15	Char	5000	Please describe other reason why
415	OUT_SRC_15	Num	8	Primary source of of day 15 information
416	OUT_SRCSPEC_15	Char	5000	Other source of day 15 information
417	OUT_DT_15	Num	8	Day that 15 day assessment was performed
418	OUT_TM_15	Num	8	Time that 15 day assessment was performed
419	COVID_OOSCALE_15	Num	8	COVID Ordinal Outcomes Scale on Day 15Select the lowest value that occurred on this study day
420	OUT_SYMPYN_15	Num	8	Did the patient report any symptoms on day 15?
421	OUT_SYMP_15___COUGH	Num	8	Which symptoms did the patient report? (choice=Cough)
422	OUT_SYMP_15___CT	Num	8	Which symptoms did the patient report? (choice=Chest tightness)

Num	Variable	Type	Len	Label
423	OUT_SYMP_15___FEVER	Num	8	Which symptoms did the patient report? (choice=Fever (temperature > 99.5°F with a thermometer))
424	OUT_SYMP_15___FEVERISH	Num	8	Which symptoms did the patient report? (choice=Feeling feverish)
425	OUT_SYMP_15___OTH	Num	8	Which symptoms did the patient report? (choice=Other)
426	OUT_SYMP_15___SOB	Num	8	Which symptoms did the patient report? (choice=Shortness of breath)
427	OUT_SYMP_15___ST	Num	8	Which symptoms did the patient report? (choice=Sore throat)
428	OUT_SYMP_15___WEAK	Num	8	Which symptoms did the patient report? (choice=Weakness or fatigue)
429	OUT_SYMPOTH_15	Char	5000	Please specify:
430	OUT_AEASSESS_15	Num	8	Adverse Event Assessment Study Day 15On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
431	OUT_AEASSESSREAS_15	Char	5000	Why were AEs not assessed?
432	OUT_SAFEASSESS_15	Num	8	Safety Outcome Assessment Study Day 15On this study day, study personnel assessed for the occurrence of safety outcomes (and if found recorded in Safety Outcomes CRF).
433	OUT_SAFEASSESSREAS_15	Char	5000	Why were safety outcomes not assessed?
434	OUT_OOSYN_29	Num	8	Was information on the COVID Ordinal Outcome Scale available at 29 days?
435	OUT_OOSNOSPEC_29	Char	5000	Please describe other reason why
436	OUT_SRC_29	Num	8	Primary source of of day 29 information
437	OUT_SRCSPEC_29	Char	5000	Other source of day 29 information
438	OUT_DT_29	Num	8	Day that 29 day assessment was performed
439	OUT_TM_29	Num	8	Time that 29 day assessment was performed
440	COVID_OOSCALE_29	Num	8	COVID Ordinal Outcomes Scale on Day 29Select the lowest value that occurred on this study day
441	OUT_SYMPYN_29	Num	8	Did the patient report any symptoms on day 29?
442	OUT_SYMP_29___COUGH	Num	8	Which symptoms did the patient report? (choice=Cough)
443	OUT_SYMP_29___CT	Num	8	Which symptoms did the patient report? (choice=Chest tightness)
444	OUT_SYMP_29___FEVER	Num	8	Which symptoms did the patient report? (choice=Fever (temperature > 99.5°F with a thermometer))
445	OUT_SYMP_29___FEVERISH	Num	8	Which symptoms did the patient report? (choice=Feeling feverish)
446	OUT_SYMP_29___OTH	Num	8	Which symptoms did the patient report? (choice=Other)
447	OUT_SYMP_29___SOB	Num	8	Which symptoms did the patient report? (choice=Shortness of breath)
448	OUT_SYMP_29___ST	Num	8	Which symptoms did the patient report? (choice=Sore throat)
449	OUT_SYMP_29___WEAK	Num	8	Which symptoms did the patient report? (choice=Weakness or fatigue)
450	OUT_SYMPOTH_29	Char	5000	Please specify:
451	OUT_AEASSESS_29	Num	8	Adverse Event Assessment Study Day 29On this study day, study personnel assessed for Adverse Events (and if found recorded AE in AE CRF).
452	OUT_AEASSESSREAS_29	Char	5000	Why were AEs not assessed?
453	OUT_SAFEASSESS_29	Num	8	Safety Outcome Assessment Study Day 29On this study day, study personnel assessed for the occurrence of safety outcomes (and if found recorded in Safety Outcomes CRF).
454	OUT_SAFEASSESSREAS_29	Char	5000	Why were safety outcomes not assessed?
455	IHO_COOSPTDISCH	Num	8	Patient discharged home according to COVID OO Scale:

Num	Variable	Type	Len	Label
456	IHO_DISCHYN	Num	8	Was the patient discharged alive from the hospital on or before study day 29?
457	IHO_DISCHDT	Num	8	Hospital Discharge Day
458	IHO_DISCHTM	Num	8	Hospital Discharge Time
459	IHO_DISCHDEST	Num	8	Patient destination at discharge:
460	IHO_CHLOR	Num	8	Did the patient receive chloroquine between randomization and hospital discharge?
461	IHO_CHLORDT	Num	8	Day of first chloroquine dose
462	IHO_CHLORTM	Num	8	Time of first chloroquine dose
463	IHO_HYDROXYCHLOR	Num	8	Did the patient receive open label hydroxychloroquine between randomization and hospital discharge?
464	IHO_HYDROXYCHLORDT	Num	8	Day of first hydroxychloroquine dose
465	IHO_HYDROXYCHLORTM	Num	8	Time of first hydroxychloroquine dose
466	IHO_REMDESIVIR	Num	8	Did the patient receive remdesivir between randomization and hospital discharge?
467	IHO_REMDESIVIRDT	Num	8	Day of first remdesivir dose
468	IHO_REMDESIVIRTM	Num	8	Time of first remdesivir dose
469	IHO_LOPINAVIR	Num	8	Did the patient receive lopinavir/ritonavir between randomization and hospital discharge?
470	IHO_LOPINAVIRDT	Num	8	Day of first lopinavir/ritonavir dose
471	IHO_LOPINAVIRTM	Num	8	Time of first lopinavir/ritonavir dose
472	IHO_AVOTH	Num	8	Did the patient receive any other antiviral between randomization and hospital discharge?
473	IHO_AVOTHSPEC	Char	5000	Name of first other antiviral
474	IHO_AVOTHDT	Num	8	Day of first dose of other antiviral
475	IHO_AVOTHTM	Num	8	Time of first dose of other antiviral
476	IHO_CONPLAS	Num	8	Did the patient receive convalescent plasma between randomization and hospital discharge?
477	IHO_CONPASDT	Num	8	Day patient first received convalescent plasma:
478	IHO_CONPASTM	Num	8	Time patient first received convalescent plasma:
479	IHO_IMMGLOB	Num	8	Did the patient receive SARS-CoV-2 hyperimmune globulin between randomization and hospital discharge?
480	IHO_IMMGLOBDT	Num	8	Day patient first received SARS-CoV-2 hyperimmune globulin:
481	IHO_IMMGLOBTM	Num	8	Time patient first received SARS-CoV-2 hyperimmune globulin:
482	IHO_MONOCANTI	Num	8	Did the patient receive monoclonal antibodies between randomization and hospital discharge?
483	IHO_MONOCANTIDT	Num	8	Day patient first received monoclonal antibodies:
484	IHO_MONOCANTITM	Num	8	Time patient first received monoclonal antibodies:
485	IHO_CORTICOSTER	Num	8	Did the patient receive corticosteroids between randomization and hospital discharge?
486	IHO_CORTICOSTERDT	Num	8	Day of first corticosteroid dose
487	IHO_CORTICOSTERTM	Num	8	Time of first corticosteroid dose

Num	Variable	Type	Len	Label
488	IHO_TOCILIZUMAB	Num	8	Did the patient receive tocilizumab between randomization and hospital discharge?
489	IHO_TOCILIZUMABDT	Num	8	Day of first tocilizumab dose
490	IHO_TOCILIZUMABTM	Num	8	Time of first tocilizumab dose
491	IHO_SARILUMAB	Num	8	Did the patient receive sarilumab between randomization and hospital discharge?
492	IHO_SARILUMABDT	Num	8	Day of first sarilumab dose
493	IHO_SARILUMABTM	Num	8	Time of first sarilumab dose
494	IHO_INTERFERON	Num	8	Did the patient receive Interferon _ between randomization and hospital discharge?
495	IHO_INTERFERONDT	Num	8	Day of first Interferon ß dose
496	IHO_INTERFERONTM	Num	8	Time of first Interferon dose
497	IHO_IMMOTH	Num	8	Did the patient receive any other immunomodulating medication between randomization and hospital discharge?
498	IHO_IMMOTHSPEC	Char	5000	Name of other immunomodulating medications
499	IHO_IMMOTHDT	Num	8	Day of first other immunomodulating medications
500	IHO_IMMOTHTM	Num	8	Time of first other immunomodulating medications
501	IHO_AZITHRO	Num	8	Did the patient receive Azithromycin between randomization and day 8?
502	IHO_AZITHRODT	Num	8	Day of first dose of Azithromycin
503	IHO_AZITHROTM	Num	8	Time of first dose of Azithromycin
504	IHO_ABOTH	Num	8	Did the patient receive any antibiotics (other than azithromycin) between randomization and day 8?
505	IHO_ABOTHDT	Num	8	Day of first dose of first other antibiotic after randomization
506	IHO_ABOTHTM	Num	8	Time of first dose of first other antibiotic after randomization
507	IHO_COVIDTTYPE_1	Num	8	Type of first SARS-CoV-2 test
508	IHO_COVIDTTYPESPEC_1	Char	5000	Other test type (1)
509	IHO_COVIDTSRC_1	Num	8	Source of specimen (1)
510	IHO_COVIDTSRCSPEC_1	Char	5000	Other specimen source (1)
511	IHO_COVIDTODT_1	Num	8	Day collected (1)
512	IHO_COVIDTOTM_1	Num	8	Time collected (1)
513	IHO_COVIDTRDT_1	Num	8	Day resulted (1)
514	IHO_COVIDTRTM_1	Num	8	Time resulted (1)
515	IHO_COVIDTRES_1	Num	8	First SARS-CoV-2 result
516	IHO_COVIDTRESSPEC_1	Char	5000	Other SARS-CoV-2 result (1)
517	IHO_COVIDTYN_2	Num	8	Was an additional SARS-CoV2 test performed?
518	IHO_COVIDTTYPE_2	Num	8	Type of second SARS-CoV-2 test
519	IHO_COVIDTTYPESPEC_2	Char	5000	Other test type (2)
520	IHO_COVIDTSRC_2	Num	8	Source of specimen (2)
521	IHO_COVIDTSRCSPEC_2	Char	5000	Other specimen source (2)
522	IHO_COVIDTODT_2	Num	8	Day collected (2)

Num	Variable	Type	Len	Label
523	IHO_COVIDTOTM_2	Num	8	Time collected (2)
524	IHO_COVIDTRDT_2	Num	8	Day resulted (2)
525	IHO_COVIDTRTM_2	Num	8	Time resulted (2)
526	IHO_COVIDTRES_2	Num	8	Second SARS-CoV-2 result
527	IHO_COVIDTRESSPEC_2	Char	5000	Other SARS-CoV-2 result (2)
528	IHO_COVIDTYN_3	Num	8	Was an additional SARS-CoV2 test performed?
529	IHO_COVIDTTYPE_3	Num	8	Type of third SARS-CoV-2 test
530	IHO_COVIDTTYPESPEC_3	Char	5000	Other test type (3)
531	IHO_COVIDTSRC_3	Num	8	Source of specimen (3)
532	IHO_COVIDTSRCSPEC_3	Char	5000	Other specimen source (3)
533	IHO_COVIDTODT_3	Num	8	Day collected (3)
534	IHO_COVIDTOTM_3	Num	8	Time collected (3)
535	IHO_COVIDTRDT_3	Num	8	Day resulted (3)
536	IHO_COVIDTRTM_3	Num	8	Time resulted (3)
537	IHO_COVIDTRES_3	Num	8	Third SARS-CoV-2 result
538	IHO_COVIDTRESSPEC_3	Char	5000	Other SARS-CoV-2 result (3)
539	IHO_COVIDTYN_4	Num	8	Was an additional SARS-CoV2 test performed?
540	IHO_COVIDTTYPE_4	Num	8	Type of fourth SARS-CoV-2 test
541	IHO_COVIDTTYPESPEC_4	Char	5000	Other test type (4)
542	IHO_COVIDTSRC_4	Num	8	Source of specimen (4)
543	IHO_COVIDTSRCSPEC_4	Char	5000	Other specimen source (4)
544	IHO_COVIDTODT_4	Num	8	Day collected (4)
545	IHO_COVIDTOTM_4	Num	8	Time collected (4)
546	IHO_COVIDTRDT_4	Num	8	Day resulted (4)
547	IHO_COVIDTRTM_4	Num	8	Time resulted (4)
548	IHO_COVIDTRES_4	Num	8	Fourth SARS-CoV-2 result
549	IHO_COVIDTRESSPEC_4	Char	5000	Other SARS-CoV-2 result (4)
550	IHO_BCULTYN	Num	8	Were any blood cultures drawn between hospital presentation and study day 7 positive?
551	IHO_BCULTDT	Num	8	Day first positive blood culture collected:
552	IHO_BCULTTM	Num	8	Time first positive blood culture collected:
553	IHO_BCULTORG___1	Num	8	Organisms identified in first positive blood culture (choice=Acinetobacter baumanii)
554	IHO_BCULTORG___10	Num	8	Organisms identified in first positive blood culture (choice=Lactobacillus)
555	IHO_BCULTORG___11	Num	8	Organisms identified in first positive blood culture (choice=Micrococcus)
556	IHO_BCULTORG___12	Num	8	Organisms identified in first positive blood culture (choice=Proteus mirabilis)
557	IHO_BCULTORG___13	Num	8	Organisms identified in first positive blood culture (choice=Pseudomonas aeruginosa)
558	IHO_BCULTORG___14	Num	8	Organisms identified in first positive blood culture (choice=Serratia marcenscens)

Num	Variable	Type	Len	Label
559	IHO_BCULTORG___15	Num	8	Organisms identified in first positive blood culture (choice=Staphylococcus aureus)
560	IHO_BCULTORG___16	Num	8	Organisms identified in first positive blood culture (choice=Stenotrophomonas maltophilia)
561	IHO_BCULTORG___17	Num	8	Organisms identified in first positive blood culture (choice=Streptococcus pneumoniae)
562	IHO_BCULTORG___18	Num	8	Organisms identified in first positive blood culture (choice=Viridans group streptococci)
563	IHO_BCULTORG___19	Num	8	Organisms identified in first positive blood culture (choice=Other)
564	IHO_BCULTORG___2	Num	8	Organisms identified in first positive blood culture (choice=Bacillus)
565	IHO_BCULTORG___3	Num	8	Organisms identified in first positive blood culture (choice=beta-hemolytic streptococci)
566	IHO_BCULTORG___4	Num	8	Organisms identified in first positive blood culture (choice=Coagulase-negative staphylococci)
567	IHO_BCULTORG___5	Num	8	Organisms identified in first positive blood culture (choice=Corynebacterium)
568	IHO_BCULTORG___6	Num	8	Organisms identified in first positive blood culture (choice=Enterobacter cloacae)
569	IHO_BCULTORG___7	Num	8	Organisms identified in first positive blood culture (choice=Enterococcus)
570	IHO_BCULTORG___8	Num	8	Organisms identified in first positive blood culture (choice=Escheria coli)
571	IHO_BCULTORG___9	Num	8	Organisms identified in first positive blood culture (choice=Klebsiella pneumoniae)
572	IHO_BCULTORGSPEC	Char	5000	Other organisms identified in first positive blood culture
573	IHO_RCULTYN	Num	8	Were any bacterial respiratory cultures (sputum, tracheal aspirate, or bronchoalveolar lavage) obtained between hospital presentation and study day 7 positive?
574	IHO_RCULTDT	Num	8	Day first positive culture collected:
575	IHO_RCULTTM	Num	8	Time first positive culture collected:
576	IHO_RCULTSRC	Num	8	Source of Culture
577	IHO_RCULTORG___1	Num	8	Organisms identified in first positive respiratory culture: (choice=Acinetobacter baumanii)
578	IHO_RCULTORG___10	Num	8	Organisms identified in first positive respiratory culture: (choice=Lactobacillus)
579	IHO_RCULTORG___11	Num	8	Organisms identified in first positive respiratory culture: (choice=Micrococcus)
580	IHO_RCULTORG___12	Num	8	Organisms identified in first positive respiratory culture: (choice=Proteus mirabilis)
581	IHO_RCULTORG___13	Num	8	Organisms identified in first positive respiratory culture: (choice=Pseudomonas aeruginosa)
582	IHO_RCULTORG___14	Num	8	Organisms identified in first positive respiratory culture: (choice=Serratia marcenscens)
583	IHO_RCULTORG___15	Num	8	Organisms identified in first positive respiratory culture: (choice=Staphylococcus aureus)
584	IHO_RCULTORG___16	Num	8	Organisms identified in first positive respiratory culture: (choice=Stenotrophomonas maltophilia)
585	IHO_RCULTORG___17	Num	8	Organisms identified in first positive respiratory culture: (choice=Streptococcus pneumoniae)

Num	Variable	Type	Len	Label
586	IHO_RCULTORG___18	Num	8	Organisms identified in first positive respiratory culture: (choice=Viridans group streptococci)
587	IHO_RCULTORG___19	Num	8	Organisms identified in first positive respiratory culture: (choice=Other)
588	IHO_RCULTORG___2	Num	8	Organisms identified in first positive respiratory culture: (choice=Bacillus)
589	IHO_RCULTORG___3	Num	8	Organisms identified in first positive respiratory culture: (choice=beta-hemolytic streptococci)
590	IHO_RCULTORG___4	Num	8	Organisms identified in first positive respiratory culture: (choice=Coagulase-negative staphylococci)
591	IHO_RCULTORG___5	Num	8	Organisms identified in first positive respiratory culture: (choice=Corynebacterium)
592	IHO_RCULTORG___6	Num	8	Organisms identified in first positive respiratory culture: (choice=Enterobacter cloacae)
593	IHO_RCULTORG___7	Num	8	Organisms identified in first positive respiratory culture: (choice=Enterococcus)
594	IHO_RCULTORG___8	Num	8	Organisms identified in first positive respiratory culture: (choice=Escheria coli)
595	IHO_RCULTORG___9	Num	8	Organisms identified in first positive respiratory culture: (choice=Klebsiella pneumoniae)
596	IHO_VIRINFYN	Num	8	Was another acute viral infection identified by clinical testing OTHER THAN SARS-CoV-2?
597	IHO_ADENOVIR	Num	8	Other acute viral infection: Adenovirus
598	IHO_ADENOVIRSRC	Num	8	Adenovirus specimen source
599	IHO_ENTEROVIR	Num	8	Other acute viral infection: Enterovirus
600	IHO_ENTEROVIRSRC	Num	8	Enterovirus specimen source
601	IHO_CORONAVIROTH	Num	8	Other acute viral infection: Coronavirus OC43, NL63, 229E, and HKU1
602	IHO_CORONAVIROTHSRC	Num	8	Coronavirus OC43, NL63, 229E, and HKU1 specimen source
603	IHO_METAPNEUMOVIR	Num	8	Other acute viral infection: Human metapneumovirus
604	IHO_METAPNEUMOVIRSRC	Num	8	Human metapneumovirus specimen source
605	IHO_FLUA	Num	8	Other acute viral infection: Influenza A
606	IHO_FLUASRC	Num	8	Influenza A specimen source
607	IHO_FLUB	Num	8	Other acute viral infection: Influenza B
608	IHO_FLUBSRC	Num	8	Influenza B specimen source
609	IHO_PARAFLU	Num	8	Other acute viral infection: Parainfluenza
610	IHO_PARAFLUSRC	Num	8	Parainfluenza specimen source
611	IHO_RHINOVIR	Num	8	Other acute viral infection: Rhinovirus
612	IHO_RHINOVIRSRC	Num	8	Rhinovirus specimen source
613	IHO_RSV	Num	8	Other acute viral infection: Respiratory Syncytial Virus
614	IHO_RSVSRC	Num	8	Respiratory Syncytial Virus specimen source
615	IHO_DVT	Num	8	Was the patient diagnosed with a deep venous thrombosis (DVT) between randomization and the first of discharge, death, or study day 29?
616	IHO_DVTDT	Num	8	Day of first study demonstrating DVT:
617	IHO_DVTTM	Num	8	Time of first study demonstrating DVT:

Num	Variable	Type	Len	Label
618	IHO_PE	Num	8	Was the patient diagnosed with a pulmonary embolism (PE) between randomization and the first of discharge, death, or study day 29?
619	IHO_PEDT	Num	8	Day of first study demonstrating PE:
620	IHO_PETM	Num	8	Time of first study demonstrating PE:
621	IHO_OXY	Num	8	Did the patient receive oxygen between randomization and the first of discharge, death, or study day 29? Supplemental oxygen is defined as oxygen administered by nasal cannula, face mask, high-flow nasal cannula, non-invasive ventilation, or invasive vent
622	IHO_OXYDT	Num	8	Day oxygen first received
623	IHO_OXYTM	Num	8	Time oxygen first received
624	IHO_OXYDISCON	Num	8	Was the patient still receiving oxygen at the first of discharge, death, or study day 29?
625	IHO_OXYDISCONDT	Num	8	Day of final discontinuation of oxygen
626	IHO_OXYDISCONTM	Num	8	Time of final discontinuation of oxygen
627	IHO_HFNC	Num	8	Did the patient receive high flow nasal cannula between randomization and the first of discharge, death, or study day 29?High flow nasal cannula refers to devices that deliver oxygen at 30 to 60 liters per minute with a titratable FiO2. Brand names include
628	IHO_HFNCDT	Num	8	Day high flow nasal cannula first received
629	IHO_HFNCTM	Num	8	Time high flow nasal cannula first received
630	IHO_HFNCDISCON	Num	8	Was the patient still receiving high flow nasal cannula at the first of discharge, death, or study day 29?
631	IHO_HFNCDISCONDT	Num	8	Day of final discontinuation of high flow nasal cannula
632	IHO_HFNCDISCONTM	Num	8	Time of final discontinuation of high flow nasal cannula
633	IHO_NIV	Num	8	Did the patient receive non-invasive ventilation (bipap) between randomization and the first of discharge, death, or study day 29?
634	IHO_NIVDT	Num	8	Day non-invasive ventilation first received
635	IHO_NIVTM	Num	8	Time non-invasive ventilation first received
636	IHO_NIVDISCON	Num	8	Was the patient still receiving non-invasive ventilation at the first of discharge, death, or study day 29?
637	IHO_NIVDISCONDT	Num	8	Day of final discontinuation
638	IHO_NIVDISCONTM	Num	8	Time of final discontinuation
639	IHO_IMV	Num	8	Did the patient receive invasive mechanical ventilation between randomization and the first of discharge, death, or study day 29?Invasive mechanical ventilation refers to ventilation via endotracheal tube or tracheostomy
640	IHO_IMVDT	Num	8	Day invasive mechanical ventilation received
641	IHO_IMVTM	Num	8	Time invasive mechanical ventilation received
642	IHO_IMVDISCON	Num	8	Was the patient still receiving invasive mechanical ventilation at the first of discharge, death or study day 29?
643	IHO_IMVDISCONDT	Num	8	Day of final discontinuation of invasive mechanical ventilation
644	IHO_IMVDISCONTM	Num	8	Time of final discontinuation of invasive mechanical ventilation
645	IHO_ECMO	Num	8	Did the patient receive extracorporeal membrane oxygenation (ECMO) between randomization and the first of discharge, death, or study day 29?
646	IHO_ECMODT	Num	8	Day ECMO first received

Num	Variable	Type	Len	Label
647	IHO_ECMOTM	Num	8	Time ECMO first received
648	IHO_ECMODISCON	Num	8	Was the patient still receiving ECMO at the first of discharge, death, or study day 29?
649	IHO_ECMODISCONDT	Num	8	Day of final discontinuation of ECMO
650	IHO_ECMODISCONTM	Num	8	Time of final discontinuation of ECMO
651	IHO_VASOP	Num	8	Did the patient receive intravenous vasopressors or inotropes between randomization and the first of discharge, death, or study day 29?
652	IHO_VASOPTYPE___1	Num	8	Check all vasopressors and inotropes the patient received (choice=Norepinephrine)
653	IHO_VASOPTYPE___2	Num	8	Check all vasopressors and inotropes the patient received (choice=Epinephrine)
654	IHO_VASOPTYPE___3	Num	8	Check all vasopressors and inotropes the patient received (choice=Vasopressin)
655	IHO_VASOPTYPE___4	Num	8	Check all vasopressors and inotropes the patient received (choice=Phenylephrine)
656	IHO_VASOPTYPE___5	Num	8	Check all vasopressors and inotropes the patient received (choice=Angiotensin II)
657	IHO_VASOPTYPE___6	Num	8	Check all vasopressors and inotropes the patient received (choice=Dobutamine)
658	IHO_VASOPTYPE___7	Num	8	Check all vasopressors and inotropes the patient received (choice=Dopamine)
659	IHO_VASOPTYPE___8	Num	8	Check all vasopressors and inotropes the patient received (choice=Milrinone)
660	IHO_VASOPDT	Num	8	Day of first receipt of vasopressors
661	IHO_VASOPTM	Num	8	Time of first receipt of vasopressors
662	IHO_VASOPDISCON	Num	8	Was the patient still receiving vasopressors at the first of discharge, death, or study day 29?
663	IHO_VASOPDISCONDT	Num	8	Day of final discontinuation of vasopressors/inotropes
664	IHO_VASOPDISCONTM	Num	8	Time of final discontinuation of vasopressors/inotropes
665	IHO_ICU	Num	8	Was the patient ever located in an ICU between randomization and the first of discharge, death, or study day 29?
666	IHO_ICUDT	Num	8	Day of ICU admission
667	IHO_ICUTM	Num	8	Time of ICU admission
668	IHO_ICUDISCH	Num	8	Was patient located in an ICU at the first of discharge, death, or study day 29?
669	IHO_ICUDISCHDT	Num	8	Day of final ICU discharge
670	IHO_ICUDISCHTM	Num	8	Time of final ICU discharge
671	SAFE_SEIZURE	Num	8	Did the patient experience seizures between randomization and day 29?
672	SAFE_SEIZUREDT	Num	8	Day of first seizure
673	SAFE_ATACH	Num	8	Did the patient experience atrial tachyarrhythmia between randomization and day 29?
674	SAFE_ATACHDT	Num	8	Day of first atrial tachyarrhythmia
675	SAFE_VTACH	Num	8	Did the patient experience ventricular tachyarrhythmia between randomization and day 29?
676	SAFE_VTACHDT	Num	8	Day of first ventricular tachyarrhythmia
677	SAFE_VTACHSPEC	Char	5000	Provide a summary of the type of ventricular tachycardia (e.g. specific mention of monomorphic or polymorphic ventricular tachycardia or torsades de points in the record), the outcome of event (e.g. did the event require chemical or electrical cardioversio

Num	Variable	Type	Len	Label
678	SAFE_CA	Num	8	Did the patient experience cardiac arrest between randomization and day 29?
679	SAFE_CADT	Num	8	Day of first cardiac arrest
680	SAFE_CASPEC	Char	5000	Provide a summary of the clinical situation leading to cardiac arrest and the outcome of the cardiac arrest. Use only deidentified information (i.e. do not provide medical record number or date of birth, and provide study days instead of exact dates).
681	SAFE_ASTALT	Num	8	Did the patient have an aspartate aminotransferase or alanine aminotransferase elevated to at least twice the local upper limit of normal between randomization and day 29?
682	SAFE_ASTALTDT	Num	8	Day of first elevation of AST or ALT at least twice the local upper limit of normal
683	SAFE_PANCR	Num	8	Did the patient have acute pancreatitis (defined by a clinically obtained lipase level above the local upper limit of normal) between randomization and day 29?
684	SAFE_PANCRDT	Num	8	Day of first meeting criteria for acute pancreatitis
685	SAFE_AKI	Num	8	Did the patient have stage II or greater acute kidney injury by KDIGO Criteria between randomization and day 29?Defined as any of the following:Creatinine 2.0-2.9 times baselineIncrease in serum creatinine above 4.0 mg/dlUrine output less than 0.5 ml/kg/h
686	SAFE_AKIDT	Num	8	Day of first meeting criteria for stage II AKI
687	SAFE_RRTNEW	Num	8	Did the patient receive new renal replacement therapy between randomization and day 29?
688	SAFE_RRTNEWDT	Num	8	Day of first receiving RRT
689	SAFE_HYPOGLY	Num	8	Did the patient experience symptomatic hypoglycemia between randomization and day 29?
690	SAFE_HYPOGLYDT	Num	8	Day of first hypoglycemic episode
691	SAFE_NEUTROP	Num	8	Did the patient experience absolute neutrophil count < 1000 (cells/mm3) between randomization and day 29?
692	SAFE_NEUTROPDT	Num	8	What was the first day on which the patient experienced neutropenia?
693	SAFE_LYMPHO	Num	8	Did the patient experience absolute lymphocyte count < 1000 (cells/mm3) between randomization and day 29?
694	SAFE_LYMPHODT	Num	8	What was the first day on which the patient experienced lymphocytopenia?
695	SAFE_ANEMIA	Num	8	Did the patient experience hemoglobin < 12.0 g/dL between randomization and day 29?
696	SAFE_ANEMIADT	Num	8	What was the first day on which the patient experienced anemia?
697	SAFE_THOMBO	Num	8	Did the patient experience a platelet count < 50 (cell/mm3; in thousands) between randomization and day 29?
698	SAFE_THOMBODT	Num	8	What was the first day on which the patient experienced thombocytopenia?
699	SAFE_DERM	Num	8	Did the patient experience a severe dermatologic reaction between randomization and day 29?
700	SAFE_DERMDT	Num	8	Day dermatologic reaction was first noted?
701	IMG_PRERAND	Num	8	Was any chest imaging available in the 48 hours prior to randomization?
702	IMG_PRERANDTYPE___1	Num	8	Type of chest imaging reviewed (choice=Chest radiogaph (X-ray))
703	IMG_PRERANDTYPE___2	Num	8	Type of chest imaging reviewed (choice=Computed Tomography (CT Chest))
704	IMG_PRERANDTYPE___3	Num	8	Type of chest imaging reviewed (choice=Other)

Num	Variable	Type	Len	Label
705	IMG_PRERANDTYPESPEC	Char	5000	Describe other type(s) of chest imaging that was obtained
706	IMG_BLARDS	Num	8	Using all available imaging, was the patient noted to have bilateral opacities/infiltrates that were not fully explained by effusions, lobar/lung collapse, nodules, cardiac failure or fluid overload prior to randomization?
707	IMG_BLARDSCLIN	Num	8	Did patient meet clinical criteria for ARDS at the time of randomization?(< 1 week of symptoms, not explained by cardiac failure, and P/F ratio < 300 or equivalent S/F ratio)
708	IMG_IH	Num	8	Was any chest imaging available between randomization and day 8?
709	IMG_IHTYPE___1	Num	8	Type of chest imaging reviewed (choice=Chest radiogaph (X-ray))
710	IMG_IHTYPE___2	Num	8	Type of chest imaging reviewed (choice=Computed Tomography (CT Chest))
711	IMG_IHTYPE___3	Num	8	Type of chest imaging reviewed (choice=Other)
712	IMG_IHTYPESPEC	Char	5000	Describe other type(s) of chest imaging that was obtained
713	IMG_IHARDS	Num	8	Using all available imaging, was the patient noted to have bilateral opacities/infiltrates that were not fully explained by effusions, lobar/lung collapse, nodules, cardiac failure or fluid overload between randomization and day 8?
714	IMG_IHARDSCLIN	Num	8	Did patient meet clinical criteria for ARDS between randomization and day 8?(< 1 week of symptoms, not explained by cardiac failure, and P/F ratio < 300 or equivalent S/F ratio)
715	IMG_ARDSDT	Num	8	Day patient first documented as having bilateral opacities/infiltrates:
716	PDO_READM	Num	8	Did the patient experience hospital readmission between discharge from the initial hospitalization and 29 days after randomization?
717	PDO_READMDT	Num	8	Day of first readmission:
718	PDO_ED	Num	8	Did the patient visit an emergency department between discharge from the initial hospitalization and 29 days after randomization?
719	PDO_EDDT	Num	8	Day of first emergency department visit:
720	PDO_OXY	Num	8	Did the patient receive supplemental oxygen between discharge from the initial hospitalization and 29 days after randomization? Supplemental oxygen is defined as oxygen administered by nasal cannula, face mask, high-flow nasal cannula, non-invasive ventil
721	PDO_OXYSTARTDT	Num	8	What was the first day on which the patient received oxygen following discharge from the index hospitalization?
722	PDO_OXYSTILL	Num	8	Is the patient still on oxygen at day 29?
723	PDO_OXYDT	Num	8	<u><I>FINAL</I></u> Day receving oxygen between discharge and day 29:
724	VS_DT	Num	8	Day this form was completed
725	VS_DIED	Num	8	Did the patient die between randomization and study day 29?
726	VS_DEATHDT	Num	8	Day of death
727	VS_DEATHHOSP	Num	8	Did the patient die prior to hospital discharge?
728	VS_ALIVEDT	Num	8	Last day known to be alive
729	AE_ID	Char	5000	AE identifier
730	AE_DT	Num	8	Day of adverse event:
731	AE_TM	Num	8	Time of adverse event:
732	AE_USERTERM	Char	500	COSTART term: [lookup tool]

Num	Variable	Type	Len	Label
733	AE_DESC	Char	5000	Description of adverse event:
734	AE_SERIOUS	Num	8	Was the adverse event serious?
735	AE_RELDRUG	Num	8	Was the adverse event related to study drug?
736	AE_UNEXPECTED	Num	8	Was the adverse event unexpected (not listed in the investigator brochure or protocol)?
737	AE_STATUS	Num	8	What was the status of the adverse event at the time of the initial AE report?
738	AE_OUTCOME	Num	8	What was the final outcome of the adverse event?
739	AE_RECDT	Num	8	Day of recovery:
740	PD_DEVDT	Num	8	Day deviation occurred:
741	PD_DEVREPDT	Num	8	Day deviation discovered:
742	PD_DEVTYPE	Num	8	Type of deviation:
743	PD_DRUGTYPE	Num	8	Type of drug error:
744	PD_OTHER	Char	5000	Please specify:
745	PD_DESC	Char	5000	Describe the deviation:
746	PD_RESOLUTION	Char	5000	Describe steps taken to resolve the deviation and prevent future occurrences:
747	PD_DRUGSTOP	Num	8	Was study drug temporarily or permanently discontinued as a result of this deviation?
748	PD_AE	Num	8	Was an adverse event reported as a result of this deviation?
749	WD_YN	Num	8	Did patient withdraw from the study?
750	WD_DT	Num	8	Day withdrawn:
751	WD_TM	Num	8	Time withdrawn:
752	WD_REAS	Num	8	Reason for patient withdrawal
753	WD_REASSPEC	Char	5000	Other reason for patient withdrawal
754	WD_REAS_V2	Num	8	Type of study withdrawal:
755	WD_DETAILS	Char	5000	Details:

Data Set Name: derived_vars.sas7bdat

Num	Variable	Type	Len	Label
1	SUBJECT_ID	Char	9	Subject ID
2	INTERVALNAME	Char	27	Enrollment record or Day 3 Assessment?
3	RAND_DT	Num	8	Randomization day
4	RAND_TM	Num	8	Randomization time
5	VS_DEATHDT	Num	8	Day of death
6	EXTRACT_DT	Num	8	Extract day
7	RAND_TRT	Num	8	Treatment arm
8	D_BL_ICU	Num	8	Baseline ICU
9	D_BMI	Num	8	BMI
10	D_COVID2	Num	8	COVID Ordinal Outcomes Scale on Day 2 (derived)
11	D_COVID3	Num	8	COVID Ordinal Outcomes Scale on Day 3 (derived)
12	D_COVID4	Num	8	COVID Ordinal Outcomes Scale on Day 4 (derived)
13	D_COVID5	Num	8	COVID Ordinal Outcomes Scale on Day 5 (derived)
14	D_COVID8	Num	8	COVID Ordinal Outcomes Scale on Day 8 (derived)
15	D_COVID15	Num	8	COVID Ordinal Outcomes Scale on Day 15 (derived)
16	D_COVID29	Num	8	COVID Ordinal Outcomes Scale on Day 29 (derived)
17	D_MORT15	Num	8	Day 15 mortality
18	D_MORT29	Num	8	Day 29 mortality
19	D_FU_DAYS	Num	8	Follow-Up Days
20	D_DOSES	Num	8	Number of Doses Administered
21	D_ECMO_DEATH	Num	8	Ecmo or Death
22	D_HOSPFREEDAYS	Num	8	Hospital Free Days
23	D_ICUFREEDAYS	Num	8	ICU Free Days
24	D_LASTALIVEDT	Num	8	Last alive day
25	D_ONSET_DURATION	Num	8	Duration of sypmtoms prior to randomization (days)
26	D_OXYFREEDAYS	Num	8	Oxygen free days
27	D_RACE	Char	80	Race
28	D_REMD_EVER	Num	8	Remdesivir (ever/never)
29	D_PFRATIO	Num	8	P/F ratio
30	D_SFRATIO	Num	8	S/F ratio
31	D_SOFA_NERVOUS	Num	8	SOFA Nervous System
32	D_SOFA_COAG	Num	8	SOFA Coagulation
33	D_SOFA_LIVER	Num	8	SOFA Liver
34	D_SOFA_RENAL	Num	8	SOFA Renal
35	D_SOFA_CARDIO	Num	8	SOFA Cardiovascular
36	D_SOFA_RESP	Num	8	SOFA Respiratory

Num	Variable	Type	Len	Label
37	D_SOFA_GCS	Num	8	Total SOFA (with GCS)
38	D_SOFA_NOGCS	Num	8	Total SOFA (without GCS)
39	D_TIME_TO_RECOVERY	Num	8	Time to recovery
40	D_VASOFREEDAYS	Num	8	Vasopressor Free Days
41	D_VENTFREEDAYS	Num	8	Ventilator Free Days
42	D_DEATHDAY	Num	8	Death day
43	D_MALE_SEX	Char	3	Sex: Male
44	D_BSTATUS_SP02	Char	3	On supplemental oxygen at baseline
45	D_BSTATUS_NO02	Char	3	Not on oxygen baseline
46	D_BL_AGE_S	Num	8	Standardized age at baseline
47	D_SOFA_GCS_S	Num	8	Standardized Total SOFA with GCS at baseline